These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23968967)

  • 1. Prevalence and management of lower urinary tract symptoms in methamphetamine abusers: an under-recognized clinical identity.
    Koo KC; Lee DH; Kim JH; Rha KH; Chung BH; Hong SJ; Mah SY
    J Urol; 2014 Mar; 191(3):722-6. PubMed ID: 23968967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re: Prevalence and management of lower urinary tract symptoms in methamphetamine abusers: an under-recognized clinical identity: K. C. Koo, D. H. Lee, J. H. Kim, K. H. Rha, B. H. Chung, S. J. Hong and S. Y. Mah. J Urol 2014; 191: 722-726.
    Gokce A; Kumsar S; Halis F
    J Urol; 2014 Oct; 192(4):1298-9. PubMed ID: 25020239
    [No Abstract]   [Full Text] [Related]  

  • 3. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desmopressin add-on therapy for refractory nocturia in men receiving α-blockers for lower urinary tract symptoms.
    Bae WJ; Bae JH; Kim SW; Chung BH; Kim JH; Kim CS; Lee HM; Lee KS; Yoo TK; Kim SI; Byun SS; Lee JY
    J Urol; 2013 Jul; 190(1):180-6. PubMed ID: 23357213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment for male lower urinary tract symptoms with anticholinergic and alpha-blockers.
    Gomelsky A; Kelly EF; Dalton DC
    Curr Opin Urol; 2018 May; 28(3):277-283. PubMed ID: 29432226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men.
    Martin S; Lange K; Haren MT; Taylor AW; Wittert G;
    J Urol; 2014 Jan; 191(1):130-7. PubMed ID: 23770136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
    Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
    J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of lower urinary tract symptoms in middle-aged and elderly Japanese.
    Osuga Y; Okamura K; Ando F; Shimokata H
    Geriatr Gerontol Int; 2013 Oct; 13(4):1010-7. PubMed ID: 23506541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of 8-mg once-daily vs 4-mg twice-daily silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (SILVER Study): a 12-week, double-blind, randomized, parallel, multicenter study.
    Choo MS; Song M; Kim JH; Lee KS; Kim JC; Kim SW; Yang SK; Lee JG; Lee JZ; Kim DK; Park WH; Kim KD; Na YG; Kwon DD; Paick JS
    Urology; 2014 Apr; 83(4):875-81. PubMed ID: 24529580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score.
    Fujimura T; Kume H; Nishimatsu H; Sugihara T; Nomiya A; Tsurumaki Y; Miyazaki H; Suzuki M; Fukuhara H; Enomoto Y; Homma Y
    BJU Int; 2012 May; 109(10):1512-6. PubMed ID: 21883834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term alpha-blockers and anticholinergic combination treatment for men with lower urinary tract symptoms in real-life practice.
    Bae WJ; Bae JH; Choi YS; Kim SJ; Cho HJ; Hong SH; Kim SW; Hwang TK; Lee JY
    Int Urol Nephrol; 2012 Aug; 44(4):1077-84. PubMed ID: 22528586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.
    van Kerrebroeck P; Chapple C; Drogendijk T; Klaver M; Sokol R; Speakman M; Traudtner K; Drake MJ;
    Eur Urol; 2013 Dec; 64(6):1003-12. PubMed ID: 23932438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin.
    Ito H; Sano F; Ogawa T; Yao M
    Int J Urol; 2014 Jan; 21(1):108-12. PubMed ID: 23662900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Male lower urinary tract symptoms: how do symptoms guide our choice of treatment?
    Gravas S; Melekos MD
    Curr Opin Urol; 2009 Jan; 19(1):49-54. PubMed ID: 19057216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
    Yokoyama O; Yoshida M; Kim SC; Wang CJ; Imaoka T; Morisaki Y; Viktrup L
    Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of targeted treatment for vesicoureteral reflux in children with nonneurogenic lower urinary tract dysfunction.
    Fast AM; Nees SN; Van Batavia JP; Combs AJ; Glassberg KI
    J Urol; 2013 Sep; 190(3):1028-32. PubMed ID: 23473909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.
    Porst H; Oelke M; Goldfischer ER; Cox D; Watts S; Dey D; Viktrup L
    Urology; 2013 Sep; 82(3):667-73. PubMed ID: 23876588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.